Yi Xing, PhD, an internationally prominent scientist in computational biology and genomics, will join Children’s Hospital of Philadelphia (CHOP) on Sept. 1 to establish a new center dedicated to harnessing big data and genomic technologies in discovering new treatment approaches for children’s health.
"Bold" is perhaps the best word to describe this week's roundup of Research Institute news, as Children's Hospital of Philadelphia nurses and investigators alike made headlines for their experimental work in pediatric CAR T-cell therapy: a cancer-fighting immunotherapy treatment that aims to re-engineer a patient's own T cells to detect and destroy tumor cells.
The Mechanistic Molecular Immunology Lab integrates cutting-edge structural biology and biochemistry tools with functional immunoassays to understand the molecular basis of immune responses to viral infections and tumors, with an emphasis on the development of novel protein-based therapeutics.
Yi Xing, PhD is Executive Director of the Department of Biomedical and Health Informatics. Dr. Xing’s groundbreaking research fits well with DBHi’s mission by merging the fields of computational biology, biomedical data science, RNA genomics, human genetics, precision medicine, and immuno-oncology. He is one of the premier investigators in this space, playing a pivotal role in developing new genomic technologies and computational methods, and leading collaborative studies aimed at understanding how the human genome and its gene products contribute to development and disease. He has an extensive publication record in bioinformatics, genomics, and RNA biology and is recognized internationally for his expertise in the fields of computational and experimental RNA biology.